Biopharma Almirall 9M sales rise on European dermatology growth
Overview
Spain biopharma's 9M 2026 net sales rose 8.3% yr/yr, led by European dermatology growth
EBITDA for 9M 2026 grew 22.7% yr/yr, margin at 24.9%
Company reiterated full-year 2026 guidance for net sales and EBITDA
Outlook
Almirall reiterates 2026 guidance for 9-12% net sales growth
Company expects 2026 EBITDA between €270 mln and €290 mln
Result Drivers
EUROPEAN DERMATOLOGY - Co said 9M sales in its European dermatology business grew 17.6% yr/yr, driven by continued momentum in key products
BIOLOGICS PORTFOLIO - Sales of Ebglyss rose 75% yr/yr to €132.1 mln and Ilumetri up 11.5% to €190.6 mln, with Ebglyss gaining market share and supported by new long-term data
BROAD DERMATOLOGY PORTFOLIO - Wynzora sales rose 15.4% to €29.3 mln and Klisyri up 18.4% to €23.8 mln, contributing to overall growth
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
9M Sales | EUR 889.20 mln | ||
9M EBITDA | EUR 221.70 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Almirall, S.A. is €14.13, about 26% above its November 6 closing price of €11.22
The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 19 three months ago
Reuters Recommended Reads
Nov 6 - India's Gland Pharma beats quarterly estimates on strong Europe, US sales
Nov 6 - Moderna swings to Q3 profit, raises outlook on strong COVID vaccine demand
Nov 6 - European stainless steelmakers see recovery pushed further into 2027
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)